1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Bliss GVS Pharma Limited

Bliss GVS Pharma Limited

BLISSGVS.BO
Bliss GVS Pharma LimitedIN flagBombay Stock Exchange
443.75
INR
+4.35
- -
46.94BMarket Cap

Total Valuation

Bliss GVS Pharma Limited carries a market capitalization of 46.94B, placing it among publicly traded companies globally. Its enterprise value stands at 21.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap46.94B
Enterprise Value21.27B

Share Statistics

Bliss GVS Pharma Limited currently has 105.79M shares outstanding.

Shares Outstanding105.79M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Bliss GVS Pharma Limited trades at a trailing price-to-earnings ratio of 17.76. The price-to-sales ratio is 2.47, and the price-to-book ratio stands at 216.82.

PE Ratio17.76
PS Ratio2.47
PB Ratio216.82
P/TBV Ratio1.87
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Bliss GVS Pharma Limited trades at an EV/EBITDA multiple of 17.90 and an EV/FCF ratio of 249.34. The EV/Sales ratio of 2.29 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.90 provides insight into valuation relative to core operating earnings.

EV / Sales2.29
EV / EBITDA17.90
EV / EBIT17.90
EV / FCF249.34

Financial Position

Bliss GVS Pharma Limited maintains a current ratio of 4.02, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.77, indicating elevated leverage, while an interest coverage ratio of 9.90 demonstrates adequate ability to service its debt obligations.

Current Ratio4.02
Quick Ratio0.96
Debt / Equity1.77
Debt / EBITDA0.18
Interest Coverage9.90

Financial Efficiency

Bliss GVS Pharma Limited posts a return on equity of 26.15 and a return on invested capital of 6.98.

Return on Equity (ROE)26.15
Return on Assets (ROA)9.25
Return on Invested Capital (ROIC)6.98
Return on Capital Employed (ROCE)22.42
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.08

Taxes

Over the trailing twelve months, Bliss GVS Pharma Limited has paid 548.62M in income taxes, reflecting an effective tax rate of 28.94.

Income Tax548.62M
Effective Tax Rate28.94

Stock Price Statistics

Bliss GVS Pharma Limited's stock has gained approximately 233.02064% over the past 52 weeks. The 50-day moving average sits at 276.88, while the 200-day moving average is 197.21.

Beta (5Y)N/A
52-Week Price Change233.02064%
50-Day Moving Average276.88
200-Day Moving Average197.21
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Bliss GVS Pharma Limited generated 9.27B in revenue and converted that into 1.29B in net income, yielding earnings per share of 12.49. EBITDA reached 1.19B, while operating income came in at 1.19B.

Revenue9.27B
Gross Profit5.02B
Operating Income1.19B
Pretax Income1.90B
Net Income1.29B
EBITDA1.19B
EBIT1.19B
Earnings Per Share (EPS)12.49

Balance Sheet

Bliss GVS Pharma Limited holds 2.27B in cash and equivalents against 217.50M in total debt, resulting in a net debt position of -322.15M. Total book value stands at 105.79M, with working capital of 7.11B providing operational flexibility.

Cash & Cash Equivalents2.27B
Total Debt217.50M
Net Debt-322.15M
Equity (Book Value)105.79M
Book Value Per Share0.99
Working Capital7.11B

Margins

Bliss GVS Pharma Limited operates with a gross margin of 54.15, reflecting its pricing power and cost economics. The operating margin of 12.82 and net profit margin of 13.93 provide insight into operational efficiency.

Gross Margin54.15
Operating Margin12.82
Pretax Margin20.45
Profit Margin13.93
EBITDA Margin12.82

Stock Splits

Bliss GVS Pharma Limited's most recent stock split took place on September 26, 2008 with a 5:8 split ratio.

Last Split Date9/26/2008
Split Ratio5:8

Scores

Bliss GVS Pharma Limited posts an Altman Z-Score of 6.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.74